Top Wall Street Analysts Share Insights on 3 High-Dividend Yield Health Care Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy VTRS?
Source: Benzinga
Investor Interest in Dividend Stocks: In uncertain market conditions, investors are increasingly drawn to dividend-yielding stocks, which typically feature companies with strong free cash flows that provide high dividend payouts.
Pfizer Inc Updates: Pfizer has a dividend yield of 6.67%. Recent analyst ratings include an Equal-Weight rating from Morgan Stanley with a price target cut to $32, and a Neutral rating from B of A Securities with a price target raised to $30. Pfizer recently completed its acquisition of Metsera, Inc.
DENTSPLY SIRONA Inc Ratings: DENTSPLY SIRONA has a dividend yield of 5.84%. Analyst Brandon Vazquez downgraded the stock to Market Perform, while UBS maintained a Buy rating but lowered the price target to $23. The company reported weaker-than-expected earnings and lowered guidance.
Viatris Inc Performance: Viatris has a dividend yield of 4.40%. Goldman Sachs initiated coverage with a Neutral rating and a $10 price target, while Piper Sandler reiterated a Neutral rating and also cut the price target to $10. Viatris reported better-than-expected quarterly earnings recently.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 15.950
Low
10.00
Averages
13.25
High
16.00
Current: 15.950
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viatris Reports Strong Q1 2026 Earnings with $3.5 Billion Revenue
- Strong Financial Performance: Viatris reported total revenues of $3.5 billion in Q1 2026, reflecting a 3% year-over-year increase, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59, indicating robust growth and profitability in the market.
- Regional Growth Drivers: The cardiovascular portfolio in Greater China drove an 18% year-over-year growth, while e-commerce sales more than doubled, enhancing the company's competitive position in the rapidly growing Asia-Pacific market and laying a foundation for future revenue growth.
- Pipeline Progress: The NDA for fast-acting meloxicam has been accepted for FDA review, with regulatory decisions expected in the second half of 2026, while the PDUFA goal dates for XULANE LO and presbyopia treatment are set for July 30 and October 17, 2026, respectively, showcasing the company's ongoing commitment to innovative drug development.
- Leadership Change and Outlook: Interim CFO Paul Campbell has taken over from former CFO Doretta Mistras, with management reaffirming confidence in their 2026 financial guidance, expecting mid- to high-single-digit growth in Greater China despite policy risks and competitive pressures in the market.
See More
Viatris Reaffirms Full-Year Outlook, Shares Surge
- Strong Earnings Beat: Viatris reported $3.5 billion in revenue for Q1 2026, exceeding consensus by $150 million with approximately 8% year-over-year growth, marking its third consecutive quarter of growth and indicating robust business recovery momentum.
- Brand Segment Growth: The Brands segment contributed $2.3 billion to revenue with around 10% year-over-year growth, driven by acceleration in Greater China and strength in Emerging Markets, further solidifying Viatris's competitive position globally.
- Profitability Improvement: The adjusted gross margin remained steady at 56%, while adjusted EBITDA and adjusted earnings per share increased by 14% and approximately 18% year-over-year to $1.0 billion and $0.59, respectively, surpassing analyst expectations and reflecting effective cost management and profitability enhancement.
- Full-Year Guidance Reaffirmed: Although the midpoint of adjusted EPS guidance at $2.40 fell short of the consensus of $2.44, the 2026 revenue guidance of $14.450 billion to $14.950 billion exceeded analyst projections, demonstrating the company's confidence in future growth.
See More
Viatris Executive Anticipates Mid to High Single-Digit Revenue Growth in Greater China by 2026 - Conference Call
Revenue Growth Expectations: Viasat executives anticipate significant growth in single-digit revenue in China by 2026.
Market Insights: The company's confidence in revenue growth is based on current market trends and demand in the region.
See More
Viatris Q1 Earnings Exceed Expectations
- Earnings Highlights: Viatris reported a Q1 non-GAAP EPS of $0.59, beating expectations by $0.09, which reflects strong profitability and boosts investor confidence in the company's financial health.
- Revenue Growth: The company achieved Q1 revenue of $3.51 billion, an 8.0% year-over-year increase, exceeding market expectations by $150 million, indicating robust demand and competitive positioning in the market.
- 2026 Guidance: Viatris projects FY26 revenue of $14.64 billion and adjusted EPS of $2.44, demonstrating confidence in future growth despite market caution regarding its long-term strategy and turnaround efforts.
- Free Cash Flow Outlook: The expected free cash flow for 2026 ranges from $1.95 billion to $2.35 billion, with a midpoint of $2.15 billion, providing essential funding for future investments and strategic restructuring initiatives.
See More
Viatris Set to Report Q1 Earnings Amid Pricing Pressures
- Earnings Expectations: Viatris is set to report its Q1 earnings on May 7, with expectations of $0.50 earnings per share, flat year-over-year, and revenue of $3.36 billion, reflecting a 3.4% increase, indicating stability amid pricing pressures in the pharmaceutical sector.
- Performance Track Record: Over the past two years, Viatris has exceeded EPS estimates 75% of the time and topped revenue expectations in 75% of its quarterly reports, showcasing a relatively consistent performance against market forecasts.
- Analyst Sentiment: Despite its historical performance, analyst sentiment has turned cautious, with four downward revisions and no upward revisions to EPS estimates in the last three months, while revenue estimates saw two upward and one downward revision, highlighting market uncertainties ahead of the earnings report.
- Market Challenges: Viatris faces challenges from generic drug pricing pressures, currency fluctuations, and broader healthcare sector uncertainties, although its Brands division achieved approximately 8% year-over-year growth driven by strength in Greater China and Emerging Markets, the overall environment remains complex.
See More
Viatris Declares $0.12 Quarterly Dividend, Maintaining 3.16% Yield
- Dividend Declaration: Viatris has declared a quarterly dividend of $0.12 per share, consistent with previous distributions, demonstrating the company's ongoing commitment to stable cash flow and shareholder returns.
- Yield Metrics: The forward yield stands at 3.16%, indicating the company's attractiveness in the current market environment, which may appeal to income-seeking investors looking for reliable returns.
- Payment Schedule: The dividend is set to be paid on June 17, with a record date of May 22 and an ex-dividend date also on May 22, ensuring shareholders receive their earnings promptly.
- Long-Term Growth Strategy: In discussing its long-term growth outlook and portfolio strategy, Viatris emphasizes continued investments across generics, established brands, and innovative medicines, aiming to enhance market competitiveness and drive future growth.
See More
Viatris Reports Strong Q1 2026 Earnings with $3.5 Billion Revenue
- Strong Financial Performance: Viatris reported total revenues of $3.5 billion in Q1 2026, reflecting a 3% year-over-year increase, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59, indicating robust growth and profitability in the market.
- Regional Growth Drivers: The cardiovascular portfolio in Greater China drove an 18% year-over-year growth, while e-commerce sales more than doubled, enhancing the company's competitive position in the rapidly growing Asia-Pacific market and laying a foundation for future revenue growth.
- Pipeline Progress: The NDA for fast-acting meloxicam has been accepted for FDA review, with regulatory decisions expected in the second half of 2026, while the PDUFA goal dates for XULANE LO and presbyopia treatment are set for July 30 and October 17, 2026, respectively, showcasing the company's ongoing commitment to innovative drug development.
- Leadership Change and Outlook: Interim CFO Paul Campbell has taken over from former CFO Doretta Mistras, with management reaffirming confidence in their 2026 financial guidance, expecting mid- to high-single-digit growth in Greater China despite policy risks and competitive pressures in the market.
See More
Viatris Reaffirms Full-Year Outlook, Shares Surge
- Strong Earnings Beat: Viatris reported $3.5 billion in revenue for Q1 2026, exceeding consensus by $150 million with approximately 8% year-over-year growth, marking its third consecutive quarter of growth and indicating robust business recovery momentum.
- Brand Segment Growth: The Brands segment contributed $2.3 billion to revenue with around 10% year-over-year growth, driven by acceleration in Greater China and strength in Emerging Markets, further solidifying Viatris's competitive position globally.
- Profitability Improvement: The adjusted gross margin remained steady at 56%, while adjusted EBITDA and adjusted earnings per share increased by 14% and approximately 18% year-over-year to $1.0 billion and $0.59, respectively, surpassing analyst expectations and reflecting effective cost management and profitability enhancement.
- Full-Year Guidance Reaffirmed: Although the midpoint of adjusted EPS guidance at $2.40 fell short of the consensus of $2.44, the 2026 revenue guidance of $14.450 billion to $14.950 billion exceeded analyst projections, demonstrating the company's confidence in future growth.
See More
Viatris Executive Anticipates Mid to High Single-Digit Revenue Growth in Greater China by 2026 - Conference Call
Revenue Growth Expectations: Viasat executives anticipate significant growth in single-digit revenue in China by 2026.
Market Insights: The company's confidence in revenue growth is based on current market trends and demand in the region.
See More
Viatris Q1 Earnings Exceed Expectations
- Earnings Highlights: Viatris reported a Q1 non-GAAP EPS of $0.59, beating expectations by $0.09, which reflects strong profitability and boosts investor confidence in the company's financial health.
- Revenue Growth: The company achieved Q1 revenue of $3.51 billion, an 8.0% year-over-year increase, exceeding market expectations by $150 million, indicating robust demand and competitive positioning in the market.
- 2026 Guidance: Viatris projects FY26 revenue of $14.64 billion and adjusted EPS of $2.44, demonstrating confidence in future growth despite market caution regarding its long-term strategy and turnaround efforts.
- Free Cash Flow Outlook: The expected free cash flow for 2026 ranges from $1.95 billion to $2.35 billion, with a midpoint of $2.15 billion, providing essential funding for future investments and strategic restructuring initiatives.
See More
Viatris Set to Report Q1 Earnings Amid Pricing Pressures
- Earnings Expectations: Viatris is set to report its Q1 earnings on May 7, with expectations of $0.50 earnings per share, flat year-over-year, and revenue of $3.36 billion, reflecting a 3.4% increase, indicating stability amid pricing pressures in the pharmaceutical sector.
- Performance Track Record: Over the past two years, Viatris has exceeded EPS estimates 75% of the time and topped revenue expectations in 75% of its quarterly reports, showcasing a relatively consistent performance against market forecasts.
- Analyst Sentiment: Despite its historical performance, analyst sentiment has turned cautious, with four downward revisions and no upward revisions to EPS estimates in the last three months, while revenue estimates saw two upward and one downward revision, highlighting market uncertainties ahead of the earnings report.
- Market Challenges: Viatris faces challenges from generic drug pricing pressures, currency fluctuations, and broader healthcare sector uncertainties, although its Brands division achieved approximately 8% year-over-year growth driven by strength in Greater China and Emerging Markets, the overall environment remains complex.
See More
Viatris Declares $0.12 Quarterly Dividend, Maintaining 3.16% Yield
- Dividend Declaration: Viatris has declared a quarterly dividend of $0.12 per share, consistent with previous distributions, demonstrating the company's ongoing commitment to stable cash flow and shareholder returns.
- Yield Metrics: The forward yield stands at 3.16%, indicating the company's attractiveness in the current market environment, which may appeal to income-seeking investors looking for reliable returns.
- Payment Schedule: The dividend is set to be paid on June 17, with a record date of May 22 and an ex-dividend date also on May 22, ensuring shareholders receive their earnings promptly.
- Long-Term Growth Strategy: In discussing its long-term growth outlook and portfolio strategy, Viatris emphasizes continued investments across generics, established brands, and innovative medicines, aiming to enhance market competitiveness and drive future growth.
See More
